Thomas Feldthus
Algemeen Directeur bij SANA AB
Vermogen: 260 795 $ op 31-05-2024
Oorsprong van het eerstegraads netwerk van Thomas Feldthus
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 27 | |
22
| Public Company | Biotechnology | 22 |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.
15
| Subsidiary | Pharmaceuticals: Major | 15 |
Saniona A/S
 Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.
7
| Subsidiary | Miscellaneous Commercial Services | 7 |
ResoTher Pharma AS
 ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors.
6
| Private Company | Pharmaceuticals: Major | 6 |
Aniona ApS
 Aniona ApS Medical/Nursing ServicesHealth Services Aniona ApS is a private company based in Ballerup, Denmark. Jørgen Drejer has been the CEOs since incorporation. The Danish company was founded by Thomas Feldthus, Anker Gunvald Lundemose, Claus Tycho Bræstrup, Jørgen Drejer.
4
| Private Company | Medical/Nursing Services | 4 |
Rehaler ApS
 Rehaler ApS Medical SpecialtiesHealth Technology Rehaler ApS develops medical devices for the treatment of migraine.
2
| Private Company | Medical Specialties | 2 |
| Public Company | Pharmaceuticals: Other | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Thomas Feldthus via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal Graduate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Founder Corporate Officer/Principal Director of Finance/CFO Corporate Officer/Principal Director/Board Member Director/Board Member | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Director of Finance/CFO Chairman Director/Board Member Founder Chief Tech/Sci/R&D Officer | |
| Copenhagen Business School | College/University | Graduate Degree Graduate Degree Graduate Degree Masters Business Admin Graduate Degree | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer Director/Board Member Chief Executive Officer Corporate Officer/Principal | |
| Scandinavian International Management Institute | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
Gyros AB
 Gyros AB Medical SpecialtiesHealth Technology Gyros AB engages in the utilization of microfluidic technologies to miniaturize and automate immunoassays. Its Gyrolab xP miniaturizes, integrates, and automates analysis of samples in parallel. The firm's technology delivers immunoassay data through automated control of centrifugal and capillary forces to steer liquid flow in proprietary nanoliter-scale microfluidic structures.The company offers Gyrolab microlaboratory, in the form of a compact disk, can process samples at nanoliter scale, controlled by Gyrolab Workstation. Gyros was founded in 2000 and is headquartered in Uppsala, Sweden. | Medical Specialties | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Biotechnology | Corporate Officer/Principal Director of Finance/CFO President Director of Finance/CFO | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| University of Aarhus | College/University | Doctorate Degree Doctorate Degree Graduate Degree Undergraduate Degree | |
| University of Southern Denmark | College/University | Undergraduate Degree Graduate Degree Doctorate Degree Graduate Degree | |
Cellectricon AB
 Cellectricon AB Miscellaneous Commercial ServicesCommercial Services Cellectricon AB provides cell-based screening services to accelerate drug discovery. The firm develops and validates exciting central nervous system and peripheral pain assays using primary cells, accelerating the path from assay validation to compound screening. Its system is equipped with an imaging-based microplate reader to simultaneously record transient fluorescence and luminescence signals, providing real-time monitoring and readouts of cell culture response. The company was founded by Jan Owe Owesson Orwar, Daniel T. Chiu and Stig Anders Jakob Lindberg in 1999 and is headquartered in Molndal, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member | |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman Director of Finance/CFO Chief Tech/Sci/R&D Officer | |
| ALLIGATOR BIOSCIENCE AB | Biotechnology | Corporate Officer/Principal Director/Board Member Chief Executive Officer | |
| BAVARIAN NORDIC A/S | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| NNIT A/S | Information Technology Services | Chairman Director/Board Member Corporate Officer/Principal | |
| BIOPORTO A/S | Medical Specialties | Director/Board Member Director/Board Member | |
Antag Therapeutics ApS
 Antag Therapeutics ApS Pharmaceuticals: MajorHealth Technology Antag Therapeutics ApS develops peptide drugs for the treatment of dietary-related metabolic diseases. It develops drugs for obesity, diabetes, and non-alcoholic fatty liver disease. The company was founded by Alexander Sparre-Ulrich and Jens Juul Holst in 2017 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| University of Lund | College/University | Doctorate Degree Graduate Degree | |
| TXP Pharma GmbH | Chief Executive Officer Founder | ||
International N&H Denmark ApS
 International N&H Denmark ApS Food: Major DiversifiedConsumer Non-Durables DuPont Nutrition Biosciences ApS is engaged in the production of food enzymes, products and pharmaceutical grade excipients for food products. It operates through the following divisions: Enablers, BioActives, Sweeteners, Cultures, Genecor and Sales and Application Food Ingredients. The Enablers division develops, produces and markets emulsifiers, hydrocolloids, and tailored systems that enable food & beverage manufactureres to make appealing products. The BioActives division is comprised of the Cultures and Sweeteners divisions. It offers food cultures and protective solutions, speciality sweeteners, health ingredients, and microorganisms for agriculture and animal nutrition. The Genencor division develops innovative enzymes and bioproducts to reduce the environmental impact of the cleaning, textile, fuel, and chemical industries. The sales and Application food Ingredients division manages and budgets global key accounts. The company was founded in 1989 and is headquartered Copenhagen, Denmark | Food: Major Diversified | Director/Board Member Director/Board Member | |
| ZEALAND PHARMA A/S | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
Bioneer A/S
 Bioneer A/S Pharmaceuticals: MajorHealth Technology Bioneer A/S develops and manufactures drugs. The firm's products and services drug development, molecular histology, dynamic gastric model, biomarkers and drug targets, protein manufacturing, mammalian cell technology, immune targeting, active ingredients and microorganisms. The company was founded in 2003 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| CURASIGHT A/S | Medical Specialties | Director/Board Member Chief Operating Officer | |
ADCendo ApS
 ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021. | Biotechnology | Founder Chairman | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Chairman Corporate Officer/Principal | |
| AP MOLLER MAERSK | Marine Shipping | Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Comptroller/Controller/Auditor Corporate Officer/Principal | |
Sophion Bioscience A/S
 Sophion Bioscience A/S Medical SpecialtiesHealth Technology Sophion Bioscience A/S develops, manufactures and markets instruments and supplies automated patch clamping. It develops throughput patch clamp solutions for functional characterization of living cells. The firm products are used in pharmaceutical and biotech companies around the world. The company was founded in July 2007 and is headquartered in Ballerup, Denmark. | Medical Specialties | Corporate Officer/Principal Director/Board Member | |
| GENMAB A/S | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Svenskt Näringsliv
 Svenskt Näringsliv Miscellaneous Commercial ServicesCommercial Services Svenskt Näringsliv provides consulting services. It focuses on protection, support, and promotion of the interests of businesses. The firm provides its members with knowledge in a number of areas including labor market and law, taxes, corporate law and intellectual property, economics and macro analysis, constitutional and legal protection, security and risk management, and trade policy. The company was founded on March 29, 2001 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
NNE A/S
 NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The company is based in Soborg, Denmark. | Engineering & Construction | Director/Board Member Chairman | |
Macrophage Pharma Ltd.
 Macrophage Pharma Ltd. BiotechnologyHealth Technology Macrophage Pharma Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Berkhamsted, the United Kingdom. | Biotechnology | Director/Board Member Chief Executive Officer | |
| BERGENBIO ASA | Pharmaceuticals: Major | Corporate Officer/Principal Chief Executive Officer | |
| ALK-ABELLÓ A/S | Biotechnology | Director/Board Member Director/Board Member | |
Novo Nordisk Region Europe A/S
 Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark. | Financial Conglomerates | Chairman Chairman | |
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Chief Executive Officer Chairman | |
| ASCENDIS PHARMA A/S | Pharmaceuticals: Major | Founder Director/Board Member | |
The Danish National Advanced Technology Foundation
 The Danish National Advanced Technology Foundation Financial ConglomeratesFinance The Danish National Advanced Technology Foundation promotes research and innovation by providing funds. It offers private companies and universities the funds and the framework for developing new and important technologies. The company was founded in 2005 and is headquartered in Copenhagen, Denmark. | Financial Conglomerates | Director/Board Member Director/Board Member |
Statistieken
Internationaal
| Denemarken | 36 |
| Zweden | 8 |
| Verenigde Staten | 4 |
| Noorwegen | 3 |
| Duitsland | 2 |
Sectoraal
| Health Technology | 29 |
| Consumer Services | 8 |
| Finance | 5 |
| Commercial Services | 4 |
| Transportation | 3 |
Operationeel
| Director/Board Member | 325 |
| Corporate Officer/Principal | 145 |
| Chairman | 124 |
| Independent Dir/Board Member | 79 |
| Chief Executive Officer | 74 |
Sterkste connecties
| Insiders | |
|---|---|
| Joseph deBethizy | 29 |
| Jesper Brandgaard | 28 |
| Jeppe Øvlesen | 27 |
| Claus Tycho Bræstrup | 27 |
| Jørgen Drejer | 26 |
| Jens Jesper Ovesen | 25 |
| Anker Gunvald Lundemose | 25 |
| Bruce Carter | 25 |
| Martin Olin | 25 |
| Anna Héléne Barnekow | 24 |
| Jan Ulf Sigvar J. Johansson | 23 |
| Robert Hoffman | 22 |
| Carl Johan Bertil Sundberg | 21 |
| Peter Nordkild | 20 |
| Per Toft Valstorp | 19 |
- Beurs
- Insiders
- Thomas Feldthus
- Bedrijfsconnecties
